Baylor College of Medicine
The goal of this study is to better understand outcomes in children with dystonic cerebral palsy (CP) receiving intrathecal baclofen (ITB), ventral dorsal rhizotomy (VDR), or deep brain stimulation (DBS) as part of standard clinical care. The decision to proceed with ITB, VDR, or DBS is made independently of research participation. The study aims to: 1. Evaluate changes in dystonia and other clinically important outcomes; 2. Identify characteristics associated with treatment response; and 3. Develop a multidimensional outcome measure for children with dystonic CP. Participants receiving ITB will follow a study-specific standardized titration protocol designed to identify a dose that provides maximum benefit with minimal side effects. Participants in all three groups will complete research assessments and questionnaires at protocol-specified timepoints to evaluate dystonia, spasticity, function, pain, stress, and quality of life.
Cerebral palsy (CP) is the most common cause of physical disability in childhood and affects \~1 in 323 in the US per the CDC. The lifetime medical costs for an individual with CP was expected to be \~$1.4 million (inflation adjusted). An effective way to improve quality of life and decrease disease burden, both in childhood and adulthood, is to significantly reduce or eliminate abnormal tone. As muscle tone subsides, it is easier to move the body both passively and actively. A reduction in tone can improve quality of life, reduce pain, ease the burden of daily care and performance of day-to-d…
Inclusion Criteria for pre-implant ITB subjects: * Child must be large enough to have an ITB pump implanted (typically \~18 kg/4 years old) * Child must be less than 21 years of age * They have a diagnosis of CP * Presence of dystonia verified with a documented Hypertonia Assessment Tool (HAT) and they must have a Barry-Albright Dystonia Scale (BADS) score \>14 * They have been identified by a physician for ITB treatment for tone management and the family/child have agreed to proceed with implantation; note: an ITB trial dose is not necessary to qualify. * Child and family are willing to part…
Intrathecal baclofen (ITB) is provided as part of standard clinical care, and the decision to proceed with ITB is made independently of research participation. Enrolled participants follow a study-specific standardized titration protocol. ITB dose is increased according to prespecified steps based on persistent hypertonia and/or potential improvement on the D-FIS, provided there are no detrimental side effects. Titration continues until dystonia and spasticity are eliminated or no longer deemed functionally impairing by the medical team, side effects limit further titration, or a maximum dose of 2,000 mcg/day is reached. If detrimental side effects occur, the dose is reduced to the previous step as needed until side effects are controlled. The final tolerated dose becomes the maintenance dose for the remainder of the study.
Ventral dorsal rhizotomy (VDR) is performed as part of standard clinical care. The decision to proceed with VDR is made independently of research participation. The study does not assign participants to VDR or modify the VDR procedure or clinical follow-up.
Deep brain stimulation (DBS) is performed as part of standard clinical care. The decision to proceed with DBS is made independently of research participation. The study does not assign participants to DBS or modify the DBS procedure or clinical follow-up.
Participants complete protocol-specified clinician or therapy assessments, patient-reported outcome measures, and study-monitoring activities at baseline and 3, 6, and 12 months. For participants receiving ITB, selected assessments and safety-monitoring activities also occur during study-specific titration visits.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.